News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Anavex 2-73 (blarcamesine) for the treatment of Rett syndrome. Fast track designation is intended to accelerate the development and review of experimental therapies aimed at treating serious or life-threatening conditions, with potential to address…

Mutations in the MECP2 gene — the most common cause of Rett syndrome — impair the activity of nerve cells in the brain that are important for learning, a study in mice reports. The findings also suggest a critical time window for treatments to be successful in people…

Scientists in Iran have identified two new mutations in the MECP2 gene in two young girls with Rett syndrome. The findings draw attention to the need to focus on a specific portion of MECP2 during genetic screening for Rett. The study, “Two novel mutations in…

Using several models of Rett syndrome, scientists have discovered a direct, time-dependent relationship between MeCP2 — the protein altered or with lowered levels in most cases of this disorder — and GABAA receptors, which are important for normal communication between nerve cells. The findings suggest that treating Rett…

A specific modification made in the huntingtin protein, which plays a key role in brain development, was able to improve motor and lung function and prolonged the survival in a mouse model of Rett syndrome, a study has found. In particular, this alteration promotes the transport of…

Researchers have identified an unusual genetic variant in the EEF1A gene as the likely cause of Rett syndrome-like disease in a young Australian girl. After standard genetic testing failed to identify the cause of her disease, researchers turned to the more advanced whole-exome sequencing (WES) technology…

Mutations that affect a specific form of the MeCP2 protein may lead to milder symptoms of Rett syndrome in males, the case report of a 9-year-old boy suggests. The study, “MeCP2_e2 partially compensates for lack of MeCP2_e1: A male case of Rett syndrome,” was published in the…

The United States Patent and Trademark Office (USPTO) granted a patent to Anavex Life Sciences covering Anavex 2-73 (blarcamesine) as a potential therapy for neurodevelopmental disorders, including Rett syndrome. The patent (No. 10,507,196) is valid until at least 2037 and also covers methods of treatment based on…

Low levels of a protein called KCC2 disrupt the ion transport balance in nerve cells and may underlie the developmental defects in people with Rett syndrome, a study says. The study, “KCC2 expression levels are reduced in post mortem brain tissue of Rett syndrome patients,” was published in…

Two new mutations causing Rett syndrome in the KIF1A and GRIN1 genes were discovered in two Chinese infants, a study reports. This research highlights the importance of an appropriate clinical follow‐up to ensure an accurate diagnosis, as some patients with genetic metabolic diseases may initially show…